-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Alzheimer's disease is one of the greatest health challenges, affecting tens of millions of people around the world
Alzheimer's disease is one of the greatest health challenges, affecting tens of millions of people around the world
With early diagnosis, we can better understand disease progression, plan and implement treatments earlier, and monitor responses to drugs currently being tested
To define Alzheimer's disease in terms of biomarkers rather than clinical assessments, Joshua Stevenson-Hoare et al.
The study included two groups of Alzheimer's disease cases (N=1439, mean age 68 years [SD=8.
The study included two groups of Alzheimer's disease cases (N=1439, mean age 68 years [SD=8.
Pearson correlation results between biomarkers in patient group (A) and control group (B)
Pearson correlation results between biomarkers in patient group (A) and control group (B)Genome-wide significant regions associated with Aβ42/Aβ40 in the patient group
Genome-wide significant regions associated with Aβ42/Aβ40 in the patient groupNo novel genome-wide significant SNPs were identified in the case-control design; however, a case-by-case analysis found two independent genome-wide significant associations between the Aβ42/Aβ40 ratio and the WWOX and COPG2 genes
No novel genome-wide significant SNPs were identified in the case-control design; however, a case-by-case analysis found two independent genome-wide significant associations between the Aβ42/Aβ40 ratio and the WWOX and COPG2 genes
Disease prediction models across all biomarker combinations indicated that the variation attributable to P-tau181 was primarily captured by APOE-ε4, while Aβ40, Aβ42, GFAP and NfL biomarkers explained additional variation above APOE
The findings suggest that currently available plasma biomarkers reflect different aspects of Alzheimer's disease, some of which are associated with aging as well as disease-specific features, while others are related to disease progression mechanisms.
However, biomarkers have the advantage of being specific compared to clinical assessments, which may confuse dementia subtypes due to phenotypic similarities .
original source
original sourceJoshua Stevenson-Hoare, Amanda Heslegrave, Ganna Leonenko, Dina Fathalla, Eftychia Bellou, Lauren Luckcuck, Rachel Marshall, Rebecca Sims, Bryan Paul Morgan, John Hardy, Bart de Strooper, Julie Williams, Henrik Zetterberg, Valentina Escott-Price, Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer's disease,Brain , 2022;, awac128, https://doi.
Joshua Stevenson-Hoare, Amanda Heslegrave, Ganna Leonenko, Dina Fathalla, Eftychia Bellou, Lauren Luckcuck, Rachel Marshall, Rebecca Sims, Bryan Paul Morgan, John Hardy, Bart de Strooper, Julie Williams, Henrik Zetterberg, Valentina Escott-Price, Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer's disease,Brain , 2022;, awac128, https://doi.
org/10.
1093/brain/awac128.
Brain left
a message here
